XML 93 R46.htm IDEA: XBRL DOCUMENT v3.20.1
License Agreements - Additional Information (Detail) - Novartis International Pharmaceutical Ltd. - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 23, 2017
May 31, 2019
May 31, 2017
Mar. 31, 2020
Dec. 31, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
License agreement termination description       The agreement may be terminated by either party upon a material breach by the other party that is not cured within 60 days after written notice. The Company may terminate the agreement in its entirety or on a product-by-product or country-by-country basis with or without cause with 60 days' prior written notice. The agreement may be terminated by either party upon a material breach by the other party that is not cured within 60 days after written notice. The Company may terminate the agreement in its entirety or on a product-by-product or country-by-country basis with or without cause with 60 days' prior written notice.
Payment for development milestone   $ 2,500,000 $ 300,000    
Maximum          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Aggregate amount payable upon satisfaction of clinical milestones $ 4,300,000        
Aggregate amount payable upon satisfaction of regulatory milestones for first indication approved 24,000,000        
Aggregate amount payable upon satisfaction of regulatory milestones for second indication approved 18,000,000        
Aggregate amount payable upon satisfaction of commercial milestones $ 125,000,000        
License Agreement | Series A Preferred Stock          
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]          
Shares issued 2,587,992        
Fair value of license agreement $ 3,200,000        
Fair value of shares issued $ 1.22